多发性骨髓瘤患者骨髓微血管密度和血清β2-微球蛋白检测的临床意义

摘要

目的 检测多发性骨髓瘤(MM)患者骨髓中血管新生的状态,探讨骨髓微血管密度(MVD)和β2-微球蛋白(β2-MG)与MM发展的关系.方法 应用改良的塑料包埋骨髓活组织病理切片和免疫组织化学染色检测患者骨髓MVD；胶乳增强免疫透射比浊法测定MM患者血清β2-MG.结果 初诊MM患者骨髓MVD明显高于正常对照组(P＜0.01),与国际预后分期(ISS)及血清β2-MG相关(P＜0.01),随临床分期的增加依次增高(P＜0.01).与治疗前相比,MM治疗有效组骨髓MVD水平明显下降(P＜0.01),治疗无效组差异无统计学意义(P＞0.05).结论 骨髓MVD及血清β2-MG检测可作为MM患者体内瘤负荷、预后及疗效判断的指标,骨髓血管新生在MM发生、发展过程中发挥重要作用,抗血管新生治疗可能成为治疗MM的新策略.%Objective To detect the microvessel density (MVD) and β2-microglobulin (β2-MG) in patients with newly diagnosed multiple myeloma ( MM), and analyze the relationship between angiogenesis with the prognosis in MM. Methods MVD was detected by plastic embedding bone marrow live histopathology and ohistochemical method. Β2-MG protein was detected with latex enhance immune transmission immunoturbidimetric assay. Results MVD and β2-MG in MM patients with newly diagnosed untreated were significantly higher than those in normal donors (P < 0.01). Those two index related to the International Staging System (ISS) (P<0.01). The levels of the two index increased by the disease stage. Compared with before treatment, the levels of the MVD and β2-MG in effective treatment group were decreased obviously after treatment (P < 0.01) , but those in un-effective treatment group were not decreased obviously after treatment ( P > 0.05 ). Conclusions M VD and serum β2-MG can be used as the prognosis and curative effect index in patients with MM. The angiogenesis in bone marrow plays an important role in the process of MM occurrence and development. Antian-giogenic therapy may be the new strategy for MM.